Informações de Exelixis Inc

Mais detalhes de Exelixis Inc Empresa

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.



Código da empresaEXEL

Nome da EmpresaExelixis Inc

Data de listagemApr 11, 2000

CEODr. Michael M. Morrissey, Ph.D.

Número de funcionários1147

Tipo de títulosOrdinary Share

Fim do ano fiscalApr 11

Endereço1851 Harbor Bay Parkway

CidadeALAMEDA

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal94502

Telefone16508377000

Sitehttps://www.exelixis.com/

Código da empresaEXEL

Data de listagemApr 11, 2000

CEODr. Michael M. Morrissey, Ph.D.

Executivos da empresa Exelixis Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Michael M. Morrissey, Ph.D.

President, Chief Executive Officer, Director

2.27M

-4.42%

Dr. Stelios B. Papadopoulos, Ph.D.

Independent Chairman of the Board, Co-Founder

1.27M

+0.78%

Mr. Jeffrey J. Hessekiel, J.D.

Executive Vice President, General Counsel

410.70K

-12.57%

Dr. Dana T. Aftab, Ph.D.

Executive Vice President - Research and Development

359.32K

-8.22%

Mr. Jack L. Wyszomierski

Independent Director

340.04K

-2.17%

Mr. Patrick Joseph Haley

Executive Vice President - Commercial

258.52K

-25.63%

Dr. George H. Poste, Ph.D.

Independent Director

159.99K

+6.53%

Dr. Maria C. Freire, Ph.D.

Independent Director

81.98K

+13.60%

Ms. Julie Anne Smith

Independent Director

10.57K

+1285.98%

Mr. Robert Lee (Bob) Oliver, Jr.

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Michael M. Morrissey, Ph.D.

President, Chief Executive Officer, Director

2.27M

-4.42%

Dr. Stelios B. Papadopoulos, Ph.D.

Independent Chairman of the Board, Co-Founder

1.27M

+0.78%

Mr. Jeffrey J. Hessekiel, J.D.

Executive Vice President, General Counsel

410.70K

-12.57%

Dr. Dana T. Aftab, Ph.D.

Executive Vice President - Research and Development

359.32K

-8.22%

Mr. Jack L. Wyszomierski

Independent Director

340.04K

-2.17%

Mr. Patrick Joseph Haley

Executive Vice President - Commercial

258.52K

-25.63%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por EmpresaUSD

Nome

Receita

Proporção

CABOMETYX

517.89M

91.14%

License revenues

49.30M

8.68%

COMETRIQ

2.12M

0.37%

Collaboration services revenues

-1.05M

-0.19%

Por RegiãoUSD

Nome

Receita

Proporção

U.S

524.77M

92.35%

Europe

37.03M

6.52%

Japan

6.46M

1.14%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

CABOMETYX

517.89M

91.14%

License revenues

49.30M

8.68%

COMETRIQ

2.12M

0.37%

Collaboration services revenues

-1.05M

-0.19%

Distribuição de ações

Atualizado em: sáb, 16 de ago

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

9.45%

Farallon Capital Management, L.L.C.

5.96%

Renaissance Technologies LLC

5.88%

State Street Investment Management (US)

4.23%

Outro

64.31%

Investidores

Proporção

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

9.45%

Farallon Capital Management, L.L.C.

5.96%

Renaissance Technologies LLC

5.88%

State Street Investment Management (US)

4.23%

Outro

64.31%

Tipos de investidores

Investidores

Proporção

Investment Advisor

44.82%

Investment Advisor/Hedge Fund

28.58%

Hedge Fund

15.52%

Research Firm

2.90%

Pension Fund

2.72%

Individual Investor

2.25%

Sovereign Wealth Fund

1.25%

Bank and Trust

0.58%

Family Office

0.19%

Outro

1.20%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

1092

260.88M

96.91%

-7.90M

2025Q2

1066

261.07M

96.97%

-18.39M

2025Q1

1059

268.29M

98.20%

-10.58M

2024Q4

992

262.76M

93.66%

-11.36M

2024Q3

924

259.58M

90.96%

-10.18M

2024Q2

908

255.61M

87.75%

-22.29M

2024Q1

905

264.69M

87.26%

-20.82M

2023Q4

882

270.85M

87.07%

-16.64M

2023Q3

847

278.02M

87.32%

-18.15M

2023Q2

833

285.95M

87.85%

-21.34M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

27.41M

10.18%

-1.20M

-4.20%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

25.44M

9.45%

-1.05M

-3.97%

Jun 30, 2025

Farallon Capital Management, L.L.C.

16.04M

5.96%

-2.60M

-13.95%

Jun 30, 2025

Renaissance Technologies LLC

15.82M

5.88%

+995.50K

+6.72%

Jun 30, 2025

State Street Investment Management (US)

11.38M

4.23%

-404.95K

-3.43%

Jun 30, 2025

Fuller & Thaler Asset Management Inc.

8.78M

3.26%

+980.50K

+12.58%

Jun 30, 2025

LSV Asset Management

7.82M

2.9%

-340.89K

-4.18%

Jun 30, 2025

AQR Capital Management, LLC

7.61M

2.83%

+712.19K

+10.33%

Jun 30, 2025

Geode Capital Management, L.L.C.

7.45M

2.77%

+28.29K

+0.38%

Jun 30, 2025

Arrowstreet Capital, Limited Partnership

5.26M

1.95%

+1.58M

+42.93%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: seg, 6 de out

Nome

Proporção

iShares Genomics Immunology and Healthcare ETF

3.48%

Invesco Dorsey Wright Healthcare Momentum ETF

3.09%

Tema Oncology ETF

2.99%

First Trust NYSE Arca Biotechnology Index Fund

2.7%

Invesco Biotechnology & Genome ETF

2.24%

SPDR S&P Biotech ETF

2.1%

First Trust NASDAQ Pharmaceuticals ETF

1.92%

Inspire Faithward Mid Cap Momentum ETF

1.84%

AAM Sawgrass US Large Cap Quality Growth ETF

1.83%

First Trust Health Care Alphadex Fund

1.82%

Ver Mais

iShares Genomics Immunology and Healthcare ETF

Proporção3.48%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporção3.09%

Tema Oncology ETF

Proporção2.99%

First Trust NYSE Arca Biotechnology Index Fund

Proporção2.7%

Invesco Biotechnology & Genome ETF

Proporção2.24%

SPDR S&P Biotech ETF

Proporção2.1%

First Trust NASDAQ Pharmaceuticals ETF

Proporção1.92%

Inspire Faithward Mid Cap Momentum ETF

Proporção1.84%

AAM Sawgrass US Large Cap Quality Growth ETF

Proporção1.83%

First Trust Health Care Alphadex Fund

Proporção1.82%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados